World's Best Scientists 2026 revealed!
Gabriella Fontanini

Gabriella Fontanini

D-Index & Metrics

Medicine

D-Index
80
Citations
23476
World Ranking
17105
National Ranking
689

Gabriella Fontanini publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gabriella Fontanini sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 425 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gabriella Fontanini D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gabriella Fontanini sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gabriella Fontanini is affiliated with the University of Pisa in Italy and has a substantial body of work within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, pathology and forensic medicine, cancer research, and molecular biology.

Their main research topics include colorectal cancer treatments and studies, cancer genomics and diagnostics, genetic factors in colorectal cancer, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, hepatocellular carcinoma treatment and prognosis, as well as occupational and environmental lung diseases.

Recent significant publications by Gabriella Fontanini include:

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial, 2022, The Lancet Oncology
  • Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review, 2020, Diagnostics
  • Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO, 2022, Journal of Clinical Oncology
  • Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries, 2020, Cancer Cytopathology

Frequent co-authors in Gabriella Fontanini's publications include:

  • Chiara Cremolini
  • Greta Alì
  • Mirella Giordano
  • Sara Lonardi
  • Clara Ugolini

Their work is regularly published in several scientific journals, with repeated contributions to:

  • Diagnostics
  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Frontiers in Oncology

Gabriella Fontanini's research contributions span a range of complex medical and biological topics that intersect oncology and molecular biology fields, with a detailed focus on colorectal and lung cancer treatment approaches as well as diagnostics. Their collaboration with prominent co-authors and presence in high-impact journals underscores ongoing engagement within the scientific community in cancer research and related medical disciplines.

Best Publications

  • Relation of neovascularisation to metastasis of non-small-cell lung cancer.

    P Macchiarini;G Fontanini;F Squartini;C.A Angeletti

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,

    Fortunato Ciardiello;Rosa Caputo;Roberto Bianco;Vincenzo Damiano

  • ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

    Francesca Carlomagno;Donata Vitagliano;Teresa Guida;Fortunato Ciardiello

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

    A D'Incecco;M. Andreozzi;V. Ludovini;E. Rossi

  • Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase

    Fortunato Ciardiello;Rosa Caputo;Vincenzo Damiano;Roberta Caputo

  • Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

    G Fontanini;S Vignati;L Boldrini;S Chinè

  • Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

    G Fontanini;M De Laurentiis;S Vignati;S Chinè

  • Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

    Gabriella Fontanini;Marco Lucchi;S Vignati;Alfredo Mussi

  • Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)

    Cataldo Bianco;Giampaolo Tortora;Roberto Bianco;Roberta Caputo

  • Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

    Gianluca Masi;Fotios Loupakis;Lisa Salvatore;Lorenzo Fornaro

  • Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

    Gabriella Fontanini;S Vignati;D Bigini;Alfredo Mussi

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion.

    Ugo Limbruno;Andrea Micheli;Marco De Carlo;Giovanni Amoroso

  • Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer

    Gabriella Fontanini;Daniela Bigini;Silvana Vignati;Fulvio Basolo

  • A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

    Iacopo Petrini;Paul S. Meltzer;In Kyu Kim;Marco Lucchi

  • Lung neuroendocrine tumours: Deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D

    Michele Simbolo;Andrea Mafficini;Katarzyna O Sikora;Matteo Fassan

  • FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

    F. Loupakis;C. Cremolini;L. Salvatore;G. Masi

  • N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression

    Fulvio Basolo;Fioravante Pisaturo;Luca E. Pollina;Gabriella Fontanini

Frequent Co-Authors

Fulvio Basolo
Fulvio Basolo University of Pisa
Alfredo Falcone
Alfredo Falcone University of Pisa
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Giampaolo Tortora
Giampaolo Tortora University of Verona
Paolo Miccoli
Paolo Miccoli University of Pisa
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna
Romano Danesi
Romano Danesi University of Pisa
Antonio Toniolo
Antonio Toniolo University of Insubria

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering Medicine in the USA opens doors to a variety of allied health and administrative careers. Many students are exploring flexible degrees through online platforms, making it easier to balance study and other commitments. Whether you want to advance in clinical practice or healthcare management, there are online options to match your interests and timeframe.

Aspiring nurse practitioners can benefit from online dnp programs that allow for doctoral-level advancement without disrupting your current role. Those seeking a quicker entry into healthcare may consider completing a fast track medical lpn course, which helps launch a practical nursing career in less time.

Specialized programs like the shortest online pmhnp programs offer an accelerated pathway towards becoming a psychiatric mental health nurse practitioner. If you’re more interested in the business and leadership side of healthcare, an online healthcare administration degree can prepare you for management roles in hospitals, clinics, and related organizations.

These related degrees and faster career tracks offer flexible opportunities for anyone looking to enter or advance within the healthcare sector.

Best Scientists Citing Gabriella Fontanini

Trending Scientists

Recently Published Articles